This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutEfficacy & SafetyDosingDosingInitiating NGENLADosing & StorageDevice DemonstrationOrdering InformationSupport & ResourcesSupport & ResourcesStarter Kits
 
Endocrine HelplineHomecare
 
Formulary PackShared Care Guide TemplateContact UsNICE RecommendationNgenla Patient Case StudiesFormulary Pack
MaterialsVideosMeetings & Events
My Ngenla PlanMy Ngenla PlanMy Ngenla PlanMy Ngenla Plan Overview 

Prescribing Information for NGENLA(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.

ORDERING INFORMATIONOrdering codes
Scroll left to view table

Product Name

PIP Code

Ngenla 24mg solution for injection in pre filled pen (GB)

540-0098

Ngenla 60mg solution for injection in pre filled pen (GB)

540-0080

Ngenla 24mg solution for injection in pre filled pen (NI)

520-2551

Ngenla 60mg solution for injection in pre filled pen (NI)

520-2569

NGENLA devices & dose increments1For more information about the device, dosing and storage, click here.

The recommended dose is 0.66mg/kg bodyweight administered once weekly by subcutaneous injection.

Scroll left to view table

Device type

Dose setting increments

Suggested dose

24mg solution for
injection pre filled pen

0.2mg

Suggested for doses less than 12mg (bodyweight <18kg).

60mg solution for
injection pre filled pen

0.5mg

Suggested for doses of 12mg and above (bodyweight 18kg or over).

Ordering needles/starter kits

The Endocrine Helpline can support patients by placing an order for consumable items such as needles, sharps bins and patient literature.

The service can also support clinicians in ordering starter kits for patients starting on NGENLA.

Pfizer will provide a box of needles as standard within the patient starter box.

For resupply, or to order additional or different needles at no cost, the patient/caregiver or Healthcare Professional can contact the Endocrine Helpline on 0800 521249 or [email protected] 

Explore more

Find out information about the starter kits available to patients starting treatment with NGENLA.

Starter Kits Loading

Access the document to support initiation of NGENLA.

Formulary pack Loading

References:

NGENLA Summary of Product Characteristics for Great Britain: https://www.medicines.org.uk/emc/search?q=ngenla & Northern Ireland: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=4319e9d0-5396-4363-8dcb-bc72051b39da&type=smpc
PP-NGE-GBR-0775. April 2024.

Learn more about how NGENLA is stored, recommended dosing, and adminstration.

Dosing & Storage Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​